Fralin Life Science Institute

Shares of BioMarin Pharmaceutical Inc. rose Friday after Citi upgraded the stock based on the sales potential for its three approved treatments, its early-stage development products and healthy cash position.

Oppenheimer & Co. started coverage on ViroPharma Inc. Friday with a "Perform" rating, taking a cautious position on the company over concern that competitors for its core products are closer to reaching the market.

Gilead Sciences, Microsoft: Money Flow Leaders Markets Data Center: Money Flow Leaders.

BioMarin Pharmaceutical Inc. today announced that Dr. Emil Kakkis, its Chief Medical Officer will retire from the company on February 27, 2009.

Heska Corporation today announced it will present at the New York Society of Security Analysts' 12th Annual Biotech and Specialty Pharma Conference on December 2, 2008 at 1177 Avenue of the Americas, 2nd Floor in New York, NY.

SOUTH SAN FRANCISCO, Calif.----Exelixis, Inc. announced today that George A. Scangos, PhD, President and Chief Executive Officer of Exelixis, will present at the Piper Jaffray 20th Annual Health Care Conference at 11:00 a.m.

Dyax Corp. said Friday the Food and Drug Administration is giving priority review to the biotechnology company's developing treatment for a genetic condition that can lead to dangerous swelling.

ALAMEDA, Calif.----On November 19, 2008 BioTime, Inc. reported financial results for the quarter ended September 30, 2008.

BEDMINSTER, N.J.----NPS Pharmaceuticals, Inc. announced today that Francois Nader, M.D., president and chief executive officer, is scheduled to present at the 20th Annual Piper Jaffray Health Care Conference in New York on Wednesday, December 3, 2008 at 12:00 p.m.

CARLSBAD, Calif.----Invitrogen Corporation and Applied Biosystems Inc. today announced the successful completion of their merger transaction. The new company will be named Life Technologies Corporation and will be traded on the NASDAQ Global Select Market under the ticker symbol "LIFE" beginning November 24, 2008.

Although not completely recession-proof, there are several key underlying characteristics that make the industry a good place to hide out in a down market.

The chief executive of Seattle-based Cell Therapeutics says he has learnt some tough lessons from his experience of integrating a pair of US and Italian biotechnology companies.

CAMBRIDGE, Mass.----Dyax Corp. announced today that the U.S. Food and Drug Administration has accepted for filing the Companyâ??s Biologics License Application for DX-88 for the treatment of acute attacks of hereditary angioedema and has designated the application for Priority Review.